Opioid agonist-antagonist combination

This page covers all Opioid agonist-antagonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Mu-opioid receptor (buprenorphine); opioid receptors (naloxone), Mu-opioid receptor (buprenorphine as partial agonist; naloxone as antagonist), Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism).

Targets

Mu-opioid receptor (buprenorphine); opioid receptors (naloxone) · Mu-opioid receptor (buprenorphine as partial agonist; naloxone as antagonist) · Mu-opioid receptor (buprenorphine); opioid receptors (naloxone antagonism) · Mu-opioid receptor (buprenorphine component); opioid receptor antagonism (samidorphan component) · Mu-opioid receptor (oxycodone agonist); opioid receptors (naltrexone antagonist) · Mu-opioid receptor (μ-OR) · Mu-opioid receptor (oxycodone); opioid receptors (naltrexone antagonism) · Mu-opioid receptor (buprenorphine partial agonist; naloxone antagonist)

Marketed (4)

• Suboxone (SCH 000484) · Merck Sharp & Dohme LLC · Psychiatry / Addiction Medicine
  Suboxone is a combination of buprenorphine (a partial opioid agonist) and naloxone (an opioid antagonist) that reduces opioid cravings and withdrawal symptoms while minimizing abuse potential.
• Buprenorphine Naloxone · Johns Hopkins University · Psychiatry / Addiction Medicine
  Buprenorphine acts as a partial mu-opioid agonist while naloxone acts as a mu-opioid antagonist, together reducing opioid cravings and withdrawal symptoms while deterring misuse.
• Zubsolv sublingual tablets · Indivior Inc. · Psychiatry / Addiction Medicine
  Zubsolv is a combination of buprenorphine and naloxone that binds to opioid receptors to reduce cravings and withdrawal symptoms in opioid use disorder.
• Buprenorphine, Naloxone Drug Combination · The University of Texas Health Science Center, Houston · Addiction Medicine / Substance Use Disorder
  Buprenorphine acts as a partial mu-opioid receptor agonist while naloxone acts as a mu-opioid receptor antagonist, together reducing opioid cravings and withdrawal symptoms while deterring misuse.

Phase 3 pipeline (7)

• Low Dose ALKS 5461 · Alkermes, Inc. · Pain Management / Opioid Use Disorder
  ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through opioid antagonism.
• High Bup/Nal Dose · New York State Psychiatric Institute · Psychiatry / Addiction Medicine
  A combination of buprenorphine (partial opioid agonist) and naloxone (opioid antagonist) at higher doses to treat opioid use disorder with improved efficacy and safety.
• Oxycodone Naltrexone (a) · Elite Laboratories, Inc · Pain Management
  Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.
• NTX/BUP · Alkermes, Inc. · Psychiatry / Addiction Medicine
  NTX/BUP is a fixed-dose combination of naltrexone (an opioid antagonist) and buprenorphine (a partial opioid agonist) that reduces opioid cravings and withdrawal symptoms while blocking euphoric effects of additional opioid use.
• Oxycodone Naltrexone (b) · Elite Laboratories, Inc · Pain Management
  Oxycodone naltrexone is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naltrexone) designed to provide analgesia while reducing opioid-related adverse effects and abuse potential.
• Low Bup/Nal Dose · New York State Psychiatric Institute · Psychiatry / Substance Use Disorder
  A combination of buprenorphine (partial opioid agonist) and naloxone (opioid antagonist) at reduced doses to treat opioid use disorder with potentially improved safety and tolerability.
• Buprenorphine/naloxone sublingual tablets · Orexo AB · Psychiatry / Addiction Medicine
  Buprenorphine acts as a partial mu-opioid receptor agonist while naloxone acts as a mu-opioid receptor antagonist, together providing opioid dependence treatment with abuse-deterrent properties.

Patent intelligence

• opioid agonist antagonist combination patent landscape — aggregated cliff calendar, attackable patents, originator estates